Scaling the druggability landscape of human bromodomains, a new class of drug targets

Journal of Medicinal Chemistry

Volumn 55, Issue 17, 2012, Pages 7342-7345

  Zhang, Guangtao ^a   Sanchez, Roberto ^a   Zhou, Ming Ming ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; G PROTEIN COUPLED RECEPTOR; HISTONE;

BINDING SITE; BROMODOMAIN; CHROMATIN STRUCTURE; DRUG TARGETING; EPIGENETICS; GENETIC TRANSCRIPTION; GENOME; HUMAN; LIGAND BINDING; NOTE; PHYSICAL CHEMISTRY; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING;

LYSINE;

EID: 84866314665     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3011977     Document Type: Note

References (38)

1. Kouzarides, T. Chromatin modifications and their function Cell 2007, 128, 693-705 (Pubitemid 46273577)
2. Dhalluin, C.; Carlson, J. E.; Zeng, L.; He, C.; Aggarwal, A. K.; Zhou, M. M. Structure and ligand of a histone acetyltransferase bromodomain Nature 1999, 399, 491-496 (Pubitemid 29258857)
3. Filippakopoulos, P.; Picaud, S.; Mangos, M.; Keates, T.; Lambert, J. P.; Barsyte-Lovejoy, D.; Felletar, I.; Volkmer, R.; Muller, S.; Pawson, T.; Gingras, A. C.; Arrowsmith, C. H.; Knapp, S. Histone recognition and large-scale structural analysis of the human bromodomain family Cell 2012, 149, 214-231
4. Jacobson, R. H.; Ladurner, A. G.; King, D. S.; Tjian, R. Structure and function of a human TAFII250 double bromodomain module Science 2000, 288, 1422-1425 (Pubitemid 30366328)
5. Owen, D. J.; Ornaghi, P.; Yang, J. C.; Lowe, N.; Evans, P. R.; Ballario, P.; Neuhaus, D.; Filetici, P.; Travers, A. A. The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase Gcn5p EMBO J. 2000, 19, 6141-6149
6. Sanchez, R.; Zhou, M. M. The role of human bromodomains in chromatin biology and gene transcription Curr. Opin. Drug Discovery Dev. 2009, 12, 659-665
7. Zeng, L.; Zhou, M. M. Bromodomain: an acetyl-lysine binding domain FEBS Lett. 2002, 513, 124-128 (Pubitemid 34242989)
8. Borah, J. C.; Mujtaba, S.; Karakikes, I.; Zeng, L.; Muller, M.; Patel, J.; Moshkina, N.; Morohashi, K.; Zhang, W.; Gerona-Navarro, G.; Hajjar, R. J.; Zhou, M. M. A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes Chem. Biol. 2011, 18, 531-541
9. Dawson, M. A.; Prinjha, R. K.; Dittmann, A.; Giotopoulos, G.; Bantscheff, M.; Chan, W. I.; Robson, S. C.; Chung, C. W.; Hopf, C.; Savitski, M. M.; Huthmacher, C.; Gudgin, E.; Lugo, D.; Beinke, S.; Chapman, T. D.; Roberts, E. J.; Soden, P. E.; Auger, K. R.; Mirguet, O.; Doehner, K.; Delwel, R.; Burnett, A. K.; Jeffrey, P.; Drewes, G.; Lee, K.; Huntly, B. J.; Kouzarides, T. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia Nature 2011, 478, 529-533
10. Delmore, J. E.; Issa, G. C.; Lemieux, M. E.; Rahl, P. B.; Shi, J.; Jacobs, H. M.; Kastritis, E.; Gilpatrick, T.; Paranal, R. M.; Qi, J.; Chesi, M.; Schinzel, A. C.; McKeown, M. R.; Heffernan, T. P.; Vakoc, C. R.; Bergsagel, P. L.; Ghobrial, I. M.; Richardson, P. G.; Young, R. A.; Hahn, W. C.; Anderson, K. C.; Kung, A. L.; Bradner, J. E.; Mitsiades, C. S. BET bromodomain inhibition as a therapeutic strategy to target c-Myc Cell 2011, 146, 904-917
11. Mertz, J. A.; Conery, A. R.; Bryant, B. M.; Sandy, P.; Balasubramanian, S.; Mele, D. A.; Bergeron, L.; Sims, R. J. Targeting MYC dependence in cancer by inhibiting BET bromodomains Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 16669-16674
12. Zhang, G.; Liu, R.; Zhong, Y.; Plotnikov, A. N.; Zhang, W.; Zeng, L.; Rusinova, E.; Gerona-Nevarro, G.; Moshkina, N.; Joshua, J.; Chuang, P. Y.; Ohlmeyer, M.; He, J. C.; Zhou, M. M. Down-regulation of NF-kappaB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition J. Biol. Chem. 2012, 287, 28840-28851
13. Zuber, J.; Shi, J.; Wang, E.; Rappaport, A. R.; Herrmann, H.; Sison, E. A.; Magoon, D.; Qi, J.; Blatt, K.; Wunderlich, M.; Taylor, M. J.; Johns, C.; Chicas, A.; Mulloy, J. C.; Kogan, S. C.; Brown, P.; Valent, P.; Bradner, J. E.; Lowe, S. W.; Vakoc, C. R. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Nature 2011, 478, 524-528
14. Vidler, L. R.; Brown, N.; Knapp, S.; Hoelder, S. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J. Med. Chem. 2012, DOI: 10.1021/jm300346w.
15. Cheng, A. C.; Coleman, R. G.; Smyth, K. T.; Cao, Q.; Soulard, P.; Caffrey, D. R.; Salzberg, A. C.; Huang, E. S. Structure-based maximal affinity model predicts small-molecule druggability Nat. Biotechnol. 2007, 25, 71-75 (Pubitemid 46087905)
16. Hajduk, P. J.; Huth, J. R.; Tse, C. Predicting protein druggability Drug Discovery Today 2005, 10, 1675-1682 (Pubitemid 41817616)
17. Halgren, T. A. Identifying and characterizing binding sites and assessing druggability J. Chem. Inf. Model. 2009, 49, 377-389
18. Krasowski, A.; Muthas, D.; Sarkar, A.; Schmitt, S.; Brenk, R. DrugPred: a structure-based approach to predict protein druggability developed using an extensive nonredundant data set J. Chem. Inf. Model. 2011, 51, 2829-2842
19. Le Guilloux, V.; Schmidtke, P.; Tuffery, P. Fpocket: an open source platform for ligand pocket detection BMC Bioinf. 2009, 10, 168
20. Nisius, B.; Sha, F.; Gohlke, H. Structure-based computational analysis of protein binding sites for function and druggability prediction J. Biotechnol. 2012, 159, 123-134
21. Schmidtke, P.; Barril, X. Understanding and predicting druggability. A high-throughput method for detection of drug binding sites J. Med. Chem. 2010, 53, 5858-5867
22. Seco, J.; Luque, F. J.; Barril, X. Binding site detection and druggability index from first principles J. Med. Chem. 2009, 52, 2363-2371
23. Sheridan, R. P.; Maiorov, V. N.; Holloway, M. K.; Cornell, W. D.; Gao, Y. D. Drug-like density: a method of quantifying the "bindability" of a protein target based on a very large set of pockets and drug-like ligands from the Protein Data Bank J. Chem. Inf. Model. 2010, 50, 2029-2040
24. Sugaya, N.; Ikeda, K. Assessing the druggability of protein-protein interactions by a supervised machine-learning method BMC Bioinf. 2009, 10, 263
25. Volkamer, A.; Kuhn, D.; Grombacher, T.; Rippmann, F.; Rarey, M. Combining global and local measures for structure-based druggability predictions J. Chem. Inf. Model. 2012, 52, 360-372
26. Dekker, F. J.; Ghizzoni, M.; van der Meer, N.; Wisastra, R.; Haisma, H. J. Inhibition of the PCAF histone acetyl transferase and cell proliferation by isothiazolones Bioorg. Med. Chem. 2009, 17, 460-466
27. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M. R.; Wang, Y.; Christie, A. L.; West, N.; Cameron, M. J.; Schwartz, B.; Heightman, T. D.; La Thangue, N.; French, C. A.; Wiest, O.; Kung, A. L.; Knapp, S.; Bradner, J. E. Selective inhibition of BET bromodomains Nature 2010, 468, 1067-1073
28. Hewings, D. S.; Wang, M.; Philpott, M.; Fedorov, O.; Uttarkar, S.; Filippakopoulos, P.; Picaud, S.; Vuppusetty, C.; Marsden, B.; Knapp, S.; Conway, S. J.; Heightman, T. D. 3,5-Dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands J. Med. Chem. 2011, 54, 6761-6770
29. Nicodeme, E.; Jeffrey, K. L.; Schaefer, U.; Beinke, S.; Dewell, S.; Chung, C. W.; Chandwani, R.; Marazzi, I.; Wilson, P.; Coste, H.; White, J.; Kirilovsky, J.; Rice, C. M.; Lora, J. M.; Prinjha, R. K.; Lee, K.; Tarakhovsky, A. Suppression of inflammation by a synthetic histone mimic Nature 2010, 468, 1119-1123
30. Sachchidanand; Resnick-Silverman, L.; Yan, S.; Mutjaba, S.; Liu, W. J.; Zeng, L.; Manfredi, J. J.; Zhou, M. M. Target structure-based discovery of small molecules that block human p53 and CREB binding protein association Chem Biol 2006, 13, 81-90 (Pubitemid 43099926)
31. Zeng, L.; Li, J.; Muller, M.; Yan, S.; Mujtaba, S.; Pan, C.; Wang, Z.; Zhou, M. M. Selective small molecules blocking HIV-1 Tat and coactivator PCAF association J. Am. Chem. Soc. 2005, 127, 2376-2377 (Pubitemid 40327786)
32. Billingsley, M. L. Druggable targets and targeted drugs: enhancing the development of new therapeutics Pharmacology 2008, 82, 239-244
33. Hopkins, A. L.; Groom, C. R. The druggable genome Nat. Rev. Drug Discovery 2002, 1, 727-730 (Pubitemid 37361545)
34. Mason, J. S.; Bortolato, A.; Congreve, M.; Marshall, F. H. New insights from structural biology into the druggability of G protein-coupled receptors Trends Pharmacol. Sci. 2012, 33, 249-260
35. Metz, A.; Ciglia, E.; Gohlke, H. Modulating protein-protein interactions: from structural determinants of binding to druggability prediction to application. Curr. Pharm. Des. [Online early access]. Published Online: May 29, 2012.
36. Reynes, C.; Host, H.; Camproux, A. C.; Laconde, G.; Leroux, F.; Mazars, A.; Deprez, B.; Fahraeus, R.; Villoutreix, B. O.; Sperandio, O. Designing focused chemical libraries enriched in protein-protein interaction inhibitors using machine-learning methods PLoS Comput. Biol. 2010, 6
37. Russ, A. P.; Lampel, S. The druggable genome: an update Drug Discovery Today 2005, 10, 1607-1610 (Pubitemid 41817609)
38. Villoutreix, B. O.; Labbé, C. M.; Lagorce, D.; Laconde, G.; Sperandio, O. A leap into the chemical space of protein-protein interaction inhibitors. Curr. Pharm. Des. [Online early access]. Published Online: May 29, 2012